Zacks Small Cap Brokers Increase Earnings Estimates for REVB

Revelation Biosciences, Inc. (NASDAQ:REVB) – Stock analysts at Zacks Small Cap increased their FY2024 earnings estimates for shares of Revelation Biosciences in a research note issued on Monday, November 11th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings of ($9.38) per share for the year, up from their prior forecast of ($16.32). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share. Zacks Small Cap also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.25) EPS.

Revelation Biosciences Trading Down 6.4 %

REVB stock opened at $0.91 on Wednesday. The firm has a 50 day moving average of $0.85 and a 200-day moving average of $1.43. The firm has a market capitalization of $1.49 million, a P/E ratio of -0.05 and a beta of 0.15. Revelation Biosciences has a 12 month low of $0.70 and a 12 month high of $25.26.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.